Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 9, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how advanced computer technology, known as machine-learning algorithms, can help improve the medical care of adults who have received heart or liver transplants. The goal is to personalize their treatment by using information from their health records, lab tests, and quality of life measures. This study is part of a larger project called DARE, which aims to create better digital health solutions for patients.
To be eligible for this trial, participants must be adults over 18 years old who had a heart or liver transplant at a specific hospital in Italy between January 2008 and December 2020 and have survived for at least six months after their surgery. They should also have attended at least one follow-up appointment for a routine check-up. Participants will not need to take any medications for this study; they will simply provide information from their medical records and assessments. It’s important to know that the trial is not currently recruiting participants, but it is designed to better understand how to tailor medical care to individual needs, potentially leading to improved health outcomes for transplant patients.
Gender
ALL
Eligibility criteria
- • Retrospective cohort Inclusion criteria Receiving a heart or liver transplantation at IRCCS AOUBO between January 2008 and December 2020.
- • Surviving at least 6 months after surgery Receiving at least one outpatient clinical assessment, comprising clinical evaluation, standard laboratory tests, and graft ultrasound Older than 18 years old
- • Exclusion criteria Unavailability of medical records in the standard data repositories of IRCCS AOUBO
- • Prospective cohort
- • Inclusion criteria Older thant 18 years old Receiving a heart or liver transplantation at least 6 months before study entry and being in active follow up at IRCCS AOUBO Obtaining informed consent
- • Exclusion criteria None
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Luciano Potena, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported